Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis COVID-19 Therapy Could Overcome Escape Variant Problem

Protein Therapeutic Enters Pivotal Trial

Executive Summary

The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.

You may also be interested in...



COVID-19: US ACTIV Study Expands To Include Three Repurposed Drugs

Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.

Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19

Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel